Literature DB >> 6117653

Effect of age and gender on disposition of temazepam.

M Divoll, D J Greenblatt, J S Harmatz, R I Shader.   

Abstract

Thirty-two male and female volunteers, 24-84 years of age, ingested single 30-mg doses of temazepam, a 3-hydroxy-1,4-benzodiazepine derivative used as a hypnotic agent. Kinetics of total and unbound temazepam were determined from multiple plasma temazepam concentrations measured during 48 hr after the dose. The temazepam elimination half-life ranged from 8 to 38 hr and was longer in women than in men (16.8 versus 12.3 hr, p less than 0.05). Likewise, clearance of total temazepam (assuming complete absorption) was higher in men than in women (1.35 versus 1.02 ml/min/kg, p less than 0.025). Neither half-life nor clearance was significantly related to age. The volume of distribution of total temazepam (mean 1.40 liters/kg) was unrelated to age or gender. Temazepam was extensively protein bound, with a mean free fraction of 2.6% (range 12.7-3.4%). The free fraction increased with age (r = 0.45, p = 0.01), partly due to the inverse relation of the free fraction to plasma albumin concentration (r = -0.34, p = 0.06) and the age-related decline in plasma albumin (r = -0.49, p less than 0.005). After correction for individual differences in binding, clearance of unbound temazepam in men was higher than in women (50.5 versus 39.7 ml/min/kg, 0.05 less than p less than 0.01), and it tended to decline with age in both sexes (r = -0.44 and -0.43, respectively, p = 0.1).

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6117653     DOI: 10.1002/jps.2600701004

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  39 in total

Review 1.  Hepatic drug metabolism and aging.

Authors:  C Durnas; C M Loi; B J Cusack
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part II).

Authors:  D J Greenblatt; J S Harmatz; R I Shader
Journal:  Clin Pharmacokinet       Date:  1991-10       Impact factor: 6.447

3.  Age-dependence and free fatty acid modulation of binding kinetics at the benzodiazepine binding site of serum albumin in neonates and adults determined using fast reaction methods.

Authors:  G Menke; P Pfister; S Sauerwein; I Rietbrock; B G Woodcock; N Rietbrock
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

4.  Adult age and ex vivo protein binding of lorazepam, oxazepam and temazepam in healthy subjects.

Authors:  Paul K L Chin; Berit P Jensen; Helle S Larsen; Evan J Begg
Journal:  Br J Clin Pharmacol       Date:  2011-12       Impact factor: 4.335

5.  Single dose pharmacokinetics and pharmacodynamics of oral loprazolam in the elderly.

Authors:  C G Swift; M R Swift; S I Ankier; A Pidgen; J Robinson
Journal:  Br J Clin Pharmacol       Date:  1985-08       Impact factor: 4.335

Review 6.  Pharmacological treatment of insomnia.

Authors:  M Maczaj
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

Review 7.  Sex-related differences in drug disposition in man.

Authors:  K Wilson
Journal:  Clin Pharmacokinet       Date:  1984 May-Jun       Impact factor: 6.447

8.  Effect of age and sex on disposition of desmethyldiazepam formed from its precursor clorazepate.

Authors:  R I Shader; D J Greenblatt; D A Ciraulo; M Divoll; J S Harmatz; A Georgotas
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

9.  Close correlation of acetaminophen clearance with that of conjugated benzodiazepines but not oxidized benzodiazepines.

Authors:  D J Greenblatt; D R Abernethy; M Divoll; R I Shader
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

10.  Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry.

Authors:  N A Dobbs; C J Twelves; H Gillies; C A James; P G Harper; R D Rubens
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.